Examkin

Question

Difficulty: EasyMonitoring and Treatment Evaluation

A 58-year-old man comes to the clinic for a follow-up visit 2 weeks after being diagnosed with primary hypertension. At his last visit, lifestyle modifications were recommended, and he was started on lisinopril. He reports feeling well and has no new symptoms. His blood pressure today is 132/84 mm Hg, and his heart rate is 72/min. Physical examination is unremarkable. Which of the following is the most appropriate next step in the management of this patient?

  1. Measure serum creatinine and potassium levelsAnswer
  2. B
    Measure serum aminotransferase levels
  3. C
    Order a renal ultrasound with Doppler flow
  4. D
    Initiate potassium chloride supplementation
  5. E
    Measure the prothrombin time and international normalized ratio

Answer

Measure serum creatinine and potassium levels
Angiotensin-converting enzyme (ACE) inhibitors, such as lisinopril, lower blood pressure by preventing the conversion of angiotensin I to angiotensin II. This leads to vasodilation of the efferent arteriole in the kidney, which can decrease intraglomerular pressure and slightly lower the glomerular filtration rate (GFR). Consequently, an acute rise in serum creatinine can occur. Furthermore, the downstream reduction in aldosterone secretion can lead to decreased renal potassium excretion, raising the risk for hyperkalemia. Therefore, standard clinical guidelines recommend checking a basic metabolic panel (specifically serum creatinine and potassium levels) 1 to 2 weeks after initiating an ACE inhibitor or angiotensin II receptor blocker (ARB) to ensure safe tolerance of the drug.

Step-by-Step Solution

1
Identify the newly initiated medication and the purpose of the follow-up visit.
The patient was started on lisinopril (an ACE inhibitor) 2 weeks ago for primary hypertension.
Different antihypertensive drug classes require specific surveillance protocols due to their unique side effect profiles.
2
Recall the physiologic effects of ACE inhibitors on the kidneys and electrolytes.
ACE inhibitors dilate the efferent arteriole, which can decrease the glomerular filtration rate. They also inhibit aldosterone, leading to potassium retention.
Understanding the mechanism of action explains why certain laboratory values might change abruptly after starting the medication.
3
Determine the appropriate guideline-concordant monitoring step.
Serum creatinine and potassium levels should be evaluated to ensure the medication is not causing acute kidney injury or dangerous hyperkalemia.
This testing confirms patient safety while assessing tolerance to the newly initiated therapy.

Key Concept

Patients initiated on angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) require monitoring of serum creatinine and potassium levels 1 to 2 weeks after starting therapy to assess for renal impairment and hyperkalemia.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic